Drugnews

Who it is for

In-depth research is designed for readers who want to connect individual news events into company fundamentals, clinical milestones, BD logic, and valuation change.

Long-term biotech company followers

Readers who want each event to connect back to pipeline value, clinical catalysts, and commercialization paths.

Investors who need industry context

Readers who follow BD, licensing, competitive dynamics, clinical risk, and capital-market repricing.

Biotech and pharma professionals

Industry readers who want a more commercial lens on pipelines, platforms, clinical data, and company positioning.

Research Packs

Turn single articles into reusable biotech research tools.

Drugnews can package high-demand topics into focused research packs for readers and teams who need a faster way to understand a market, valuation question, or BD decision.

Investment Framework

GLP-1 and Obesity Drug Competition Map

A structured view of Novo Nordisk, Lilly, oral GLP-1s, combination therapies, and next-generation obesity pipelines, focused on product, supply-chain, and commercialization advantage.

PDF / chart packFor investors and industry readers
View related in-depth research
BD / Licensing

Pipeline Valuation and Licensing-Terms Pack

A practical framework for rNPV, upfront payments, milestones, royalties, territorial rights, and how buyers price an asset before it reaches the market.

Valuation frameworkFor research and BD teams
View related in-depth research
Company Service

Biotech IR Content Audit

A focused review of a company's website, deck, press releases, and investor materials to clarify clinical evidence, commercialization path, competitor positioning, and catalysts.

30-minute consultationFor company and IR teams
Book an audit

In-depth research FAQ

A research radar, not isolated articles.

In-depth research connects individual events back to company value, clinical milestones, licensing terms, and capital-market judgment.

How is Drugnews in-depth research different from business analysis?

Business analysis explains public events. In-depth research connects company tracking, industry context, valuation frameworks, BD terms, and capital-market judgment into a repeatable research system.

Who is Drugnews in-depth research for?

It is designed for biotech investors, industry professionals, research and BD teams, and readers who want commercial judgment around clinical data and company strategy.

Which topic should I start with?

Readers interested in GLP-1, obesity drugs, pipeline valuation, or licensing transactions can start from the matching in-depth articles and research packs. Company teams can start with an IR content audit.

What value does a subscription provide?

Subscribers get a more systematic way to track company fundamentals, clinical milestones, BD/licensing, valuation changes, and industry competition.